HIF-1α overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis.
Angiogenesis
Exosome
HIF-1α
Mesenchymal stem cell
Myocardial infarction
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
28 08 2020
28 08 2020
Historique:
received:
19
01
2020
accepted:
09
08
2020
revised:
26
06
2020
entrez:
30
8
2020
pubmed:
30
8
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Myocardial infarction (MI) is a severe disease that often associated with dysfunction of angiogenesis. Cell-based therapies for MI using mesenchymal stem cell (MSC)-derived exosomes have been well studied due to their strong proangiogenic effect. Genetic modification is one of the most common methods to enhance exosome therapy. This study investigated the proangiogenic and cardioprotective effect of exosomes derived from hypoxia-inducible factor 1-alpha (HIF-1α)-modified MSCs. Lentivirus containing HIF-1α overexpressing vector was packaged and used to infect MSCs. Exosomes were isolated from MSC-conditioned medium by ultracentrifugation. Human umbilical vein endothelial cells (HUVECs) were treated under hypoxia condition for 48 h co-cultured with PBS, control exosomes, or HIF-1α-overexpressed exosomes, respectively. Then the preconditioned HUVECs were subjected to tube formation assay, Transwell assay, and EdU assay to evaluate the protective effect of exosomes. Meanwhile, mRNA and secretion levels of proangiogenic factors were measured by RT-qPCR and ELISA assays. In vivo assays were conducted using the rat myocardial infarction model. PBS, control exosomes, or HIF-1α-overexpressed exosomes were injected through tail vein after MI surgery. Heart function was assessed by echocardiography at days 3, 14, and 28. At day 7, mRNA and protein expression levels of proangiogenic factors in the peri-infarction area and circulation were evaluated, respectively. At day 28, hearts were collected and subjected to H&E staining, Masson's trichrome staining, and immunofluorescent staining. HIF-1α-overexpressed exosomes rescued the impaired angiogenic ability, migratory function, and proliferation of hypoxia-injured HUVECs. Simultaneously, HIF-1α-overexpressed exosomes preserved heart function by promoting neovessel formation and inhibiting fibrosis in the rat MI model. In addition, both in vitro and in vivo proangiogenic factors mRNA and protein expression levels were elevated after HIF-1α-overexpressed exosome application. HIF-1α-overexpressed exosomes could rescue the impaired angiogenic ability, migration, and proliferation of hypoxia-pretreated HUVECs in vitro and mediate cardioprotection by upregulating proangiogenic factors and enhancing neovessel formation.
Sections du résumé
BACKGROUND
Myocardial infarction (MI) is a severe disease that often associated with dysfunction of angiogenesis. Cell-based therapies for MI using mesenchymal stem cell (MSC)-derived exosomes have been well studied due to their strong proangiogenic effect. Genetic modification is one of the most common methods to enhance exosome therapy. This study investigated the proangiogenic and cardioprotective effect of exosomes derived from hypoxia-inducible factor 1-alpha (HIF-1α)-modified MSCs.
METHODS
Lentivirus containing HIF-1α overexpressing vector was packaged and used to infect MSCs. Exosomes were isolated from MSC-conditioned medium by ultracentrifugation. Human umbilical vein endothelial cells (HUVECs) were treated under hypoxia condition for 48 h co-cultured with PBS, control exosomes, or HIF-1α-overexpressed exosomes, respectively. Then the preconditioned HUVECs were subjected to tube formation assay, Transwell assay, and EdU assay to evaluate the protective effect of exosomes. Meanwhile, mRNA and secretion levels of proangiogenic factors were measured by RT-qPCR and ELISA assays. In vivo assays were conducted using the rat myocardial infarction model. PBS, control exosomes, or HIF-1α-overexpressed exosomes were injected through tail vein after MI surgery. Heart function was assessed by echocardiography at days 3, 14, and 28. At day 7, mRNA and protein expression levels of proangiogenic factors in the peri-infarction area and circulation were evaluated, respectively. At day 28, hearts were collected and subjected to H&E staining, Masson's trichrome staining, and immunofluorescent staining.
RESULTS
HIF-1α-overexpressed exosomes rescued the impaired angiogenic ability, migratory function, and proliferation of hypoxia-injured HUVECs. Simultaneously, HIF-1α-overexpressed exosomes preserved heart function by promoting neovessel formation and inhibiting fibrosis in the rat MI model. In addition, both in vitro and in vivo proangiogenic factors mRNA and protein expression levels were elevated after HIF-1α-overexpressed exosome application.
CONCLUSION
HIF-1α-overexpressed exosomes could rescue the impaired angiogenic ability, migration, and proliferation of hypoxia-pretreated HUVECs in vitro and mediate cardioprotection by upregulating proangiogenic factors and enhancing neovessel formation.
Identifiants
pubmed: 32859268
doi: 10.1186/s13287-020-01881-7
pii: 10.1186/s13287-020-01881-7
pmc: PMC7455909
doi:
Substances chimiques
Hif1a protein, rat
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
373Références
Stem Cells Int. 2019 Sep 9;2019:7132708
pubmed: 31582986
Biol Chem. 1997 Jul;378(7):609-16
pubmed: 9278140
Acta Pharmacol Sin. 2010 Sep;31(9):1085-94
pubmed: 20711226
Circ Res. 2007 Dec 7;101(12):1310-8
pubmed: 17932327
Stem Cells Int. 2018 Nov 25;2018:7045245
pubmed: 30622568
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
Front Immunol. 2014 Dec 03;5:608
pubmed: 25520717
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Nat Med. 2003 May;9(5):604-13
pubmed: 12669032
Methods Mol Biol. 2020;2150:213-225
pubmed: 30941719
Am J Respir Cell Mol Biol. 2016 Nov;55(5):736-748
pubmed: 27391108
J Interv Cardiol. 2020 Apr 6;2020:6980324
pubmed: 32327944
J Cell Mol Med. 2006 Jan-Mar;10(1):45-55
pubmed: 16563221
J Am Heart Assoc. 2018 Aug 7;7(15):e008737
pubmed: 30371236
Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
J Am Coll Cardiol. 2005 Dec 6;46(11):2116-24
pubmed: 16325051
J Cell Biochem. 2018 Jul;119(7):5274-5286
pubmed: 29266431
Nat Med. 2004 Aug;10(8):858-64
pubmed: 15235597
J Thorac Dis. 2018 Sep;10(9):5476-5488
pubmed: 30416797
Proteomics. 2013 Sep;13(17):2670-81
pubmed: 23798543
Stem Cells Int. 2018 Sep 9;2018:3290372
pubmed: 30271437
Microvasc Res. 2011 Jan;81(1):26-33
pubmed: 20937289
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Stem Cells. 2017 Jul;35(7):1747-1759
pubmed: 28376567
Am J Physiol Cell Physiol. 2005 Feb;288(2):C314-20
pubmed: 15496478
Nat Commun. 2019 Feb 27;10(1):959
pubmed: 30814518
Circulation. 2003 Jul 8;108(1):79-85
pubmed: 12796124
Mol Ther. 2015 May;23(5):812-823
pubmed: 25868399
Cell. 1997 Apr 4;89(1):9-12
pubmed: 9094708
Stem Cell Res Ther. 2017 Aug 3;8(1):182
pubmed: 28774328
Cell Mol Life Sci. 2020 Jan;77(2):253-265
pubmed: 31468060
Cell Physiol Biochem. 2015;37(6):2415-24
pubmed: 26646808
Stem Cells Transl Med. 2017 Jan;6(1):51-59
pubmed: 28170176
Cell Physiol Biochem. 2018;50(6):2329-2340
pubmed: 30423574
Stem Cell Res Ther. 2017 Nov 25;8(1):268
pubmed: 29178928
Stem Cells Int. 2015;2015:659890
pubmed: 26074976
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Cancer Sci. 2018 Mar;109(3):560-571
pubmed: 29285833
Circ Res. 2011 Sep 30;109(8):923-40
pubmed: 21960725
Clin Cancer Res. 2009 May 15;15(10):3462-71
pubmed: 19447872